IPHA Innate Pharma S.A.

6.5
-0.15  -2%
Previous Close 6.65
Open 6.37
Price To Book 2.17
Market Cap 512,717,979
Shares 78,879,689
Volume 4,828
Short Ratio
Av. Daily Volume 15,707
Stock charts supplied by TradingView

NewsSee all news

  1. Outcome Of Annual General Meeting Of May 19, 2020

    MARSEILLE, France, May 20, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") announces the results of the vote of its shareholders at the Annual General Meeting ("AGM")

  2. Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program

    Phase II expansion cohort of "IO-pretreated patients" demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation MARSEILLE, France, May 14, 2020 (GLOBE

  3. Innate Pharma First Quarter 2020 Report

    Cash, cash equivalents and financial assets of the Company amounted to €206.9 millioniFirst patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumoniaFirst patient dosed

  4. Number of Shares and Voting Rights of Innate Pharma as at May 1, 2020

    MARSEILLE, France, May 06, 2020 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers,

  5. First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

    MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in a randomized, double-blind Phase II

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial ongoing.
Monalizumab and durvalumab
Solid tumors
Phase 2 cohort 3 data due 2H 2020.
Monalizumab in combination with cetuximab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase 1/2 expansion cohort initial data due 2H 2020.
IPH5401 STELLAR-001
Non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC)
Phase 2 trial placed on partial clinical hold - noted January 9, 2020.
IPH4102 - TELLOMAK
Mycosis Fungoides and Peripheral T-cell Lymphoma
Phase 1 initiation of dosing announced March 9, 2020.
IPH5201
Solid tumors

Latest News

  1. Outcome Of Annual General Meeting Of May 19, 2020

    MARSEILLE, France, May 20, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") announces the results of the vote of its shareholders at the Annual General Meeting ("AGM")

  2. Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program

    Phase II expansion cohort of "IO-pretreated patients" demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation MARSEILLE, France, May 14, 2020 (GLOBE

  3. Innate Pharma First Quarter 2020 Report

    Cash, cash equivalents and financial assets of the Company amounted to €206.9 millioniFirst patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumoniaFirst patient dosed

  4. Number of Shares and Voting Rights of Innate Pharma as at May 1, 2020

    MARSEILLE, France, May 06, 2020 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers,

  5. First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

    MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in a randomized, double-blind Phase II

  6. Innate Pharma Files Its 2019 Universal Registration Document (Document d'enregistrement universel) and Its 2019 Annual Report on Form 20-F

    MARSEILLE, France, April 24, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced the filing of its 2019 Universal Registration Document (Document

  7. Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders

    MARSEILLE, France, April 14, 2020 (GLOBE NEWSWIRE) -- Innate Pharma (the "Company" - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders ("AGM") on May 19, 2020 AM in its

  8. Innate Pharma Reports Full Year 2019 Financial Results and Business Update

    Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million1)Monalizumab to advance to a Phase III clinical trial in

  9. GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

    TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™)

  10. French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

    Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase

  11. Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial

    MARSEILLE, France, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the

  12. The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia

    MARSEILLE, France, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the European Medicines Agency (EMA) has accepted the Marketing

  13. Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

    MARSEILLE, France, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety

  14. Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019

    MARSEILLE, France, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab

  15. INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020

    Innate Pharma SA ((the "Company" - Euronext Paris: FR0010331421 – IPH, NASDAQ:IPHA) today released its 2020 financial calendar: March 10, 2020:         Publication of 2019 financial statements, with management

  16. Innate Pharma Certified as a Great Place to Work®

    Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) today announced its certification as a great work place by the independent institute, Great Place to Work®, a global authority on workplace culture, employee experience and

  17. Innate Pharma third quarter 2019 report

    Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni $79.1 million (€71.4 millionii) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to advance to

  18. Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting

    Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Marseille, France, November 7, 2019, 7:00 AM CET Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the

  19. Innate Pharma announces preclinical data presentations at SITC 2019

    Preclinical data showcases advancement of its immuno-oncology portfolio across the Company's three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment Marseille, France,

  20. Innate Pharma Announces Closing of Global Offering

    INNATE PHARMA S.A. (OTC:IPHYF, NASDAQ:IPHA) ("Innate Pharma" or the "Company"), a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to